Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Kiniksa Pharmaceuticals develops and commercializes biologic therapies targeting inflammatory and autoimmune diseases, primarily focusing on cardiovascular conditions like recurrent pericarditis. Its portfolio includes ARCALYST, an IL-1 cytokine trap, and investigational monoclonal antibodies such as KPL-387 and KPL-1161. The company partners globally, leveraging licensing, out-licensing, and strategic collaborations to advance innovative treatments for unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.